MXPA02005563A - Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. - Google Patents

Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.

Info

Publication number
MXPA02005563A
MXPA02005563A MXPA02005563A MXPA02005563A MXPA02005563A MX PA02005563 A MXPA02005563 A MX PA02005563A MX PA02005563 A MXPA02005563 A MX PA02005563A MX PA02005563 A MXPA02005563 A MX PA02005563A MX PA02005563 A MXPA02005563 A MX PA02005563A
Authority
MX
Mexico
Prior art keywords
preparation
interferon
stable
aqua formulation
formulation
Prior art date
Application number
MXPA02005563A
Other languages
English (en)
Inventor
Zhang Lei
Original Assignee
Tianjin Hualida Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hualida Biotechnology filed Critical Tianjin Hualida Biotechnology
Publication of MXPA02005563A publication Critical patent/MXPA02005563A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a una formulacion estable de interferon-alfa en solucion acuosa que puede estar libre de conservadores o ingredientes extraidos de la sangre humana, la cual comprende los siguientes componentes: a. interferon-alfa; b. un sistema regulador para mantener el pH dentro de un rango de 4.5 a 9.0; c. un agente estabilizante; d. un tensoactivo no ionico; e. un regulador de la presion osmotica La presente invencion tambien se refiere al metodo de preparacion y a los usos de dichas soluciones en el tratamiento de enfermedades virales, tumorales e inmunitarias.
MXPA02005563A 1999-12-06 2000-12-05 Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. MXPA02005563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB991255828A CN1175901C (zh) 1999-12-06 1999-12-06 一种稳定的干扰素水溶液
PCT/CN2000/000531 WO2001041793A1 (fr) 1999-12-06 2000-12-05 Formulation stable d'interferon en solution, son procede de preparation et ses applications

Publications (1)

Publication Number Publication Date
MXPA02005563A true MXPA02005563A (es) 2004-09-10

Family

ID=5284022

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005563A MXPA02005563A (es) 1999-12-06 2000-12-05 Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.

Country Status (10)

Country Link
US (1) US20030170207A1 (es)
EP (1) EP1250932B1 (es)
CN (1) CN1175901C (es)
AT (1) ATE460175T1 (es)
AU (1) AU1848901A (es)
BR (1) BR0016304A (es)
DE (1) DE60043994D1 (es)
MX (1) MXPA02005563A (es)
RU (1) RU2242242C2 (es)
WO (1) WO2001041793A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
CA2566364A1 (en) 2004-05-17 2005-11-24 Ares Trading S.A. Hydrogel interferon formulations
WO2005117949A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Stabilized interferon liquid formulations
CN1724567B (zh) * 2004-07-22 2010-08-18 北京三元基因工程有限公司 一种稳定的重组人干扰素α1b水溶液
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
JP5563475B2 (ja) 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102988984B (zh) * 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
RU2564951C1 (ru) * 2014-08-28 2015-10-10 Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") Композиция водного раствора рекомбинантного интерферона альфа-2 человека для ректального применения
CN106421755A (zh) * 2016-11-03 2017-02-22 广州凯耀资产管理有限公司 一种干扰素组合物及其制备方法
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用
CN115177719A (zh) * 2022-07-29 2022-10-14 广州源博医药科技有限公司 一种犬α干扰素水针剂型及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6261800B1 (en) * 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤

Also Published As

Publication number Publication date
DE60043994D1 (de) 2010-04-22
EP1250932A1 (en) 2002-10-23
RU2242242C2 (ru) 2004-12-20
BR0016304A (pt) 2002-11-05
CN1175901C (zh) 2004-11-17
ATE460175T1 (de) 2010-03-15
RU2002118115A (ru) 2004-02-20
WO2001041793A1 (fr) 2001-06-14
CN1256148A (zh) 2000-06-14
EP1250932A4 (en) 2006-04-19
EP1250932B1 (en) 2010-03-10
US20030170207A1 (en) 2003-09-11
AU1848901A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
MY125356A (en) Moxifloxacin/sodium chloride formulation
DE50000639D1 (de) Verfahren zur stabilisierung von polyvinylpyrrolidon-zubereitungen
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
HUT75310A (en) Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
ATE515258T1 (de) Mukosales verabreichungssytem
GEP20022751B (en) Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
EP0967276A3 (en) Anti-tumor agent comprising salmosin
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
AU4300700A (en) Inactivated cytokines for immunisation
EP0974360A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
HK1039935A1 (en) Use of (1r, 4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol in hbv
ATE350026T1 (de) Erhaltung von körpereigenen proteinen
TNSN03066A1 (en) Natural antibodies active against hiv virus

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration